3K3A-APC

BIOLOGICAL2 trials

Sponsors

ZZ Biotech, LLC

Conditions

Ischemic Stroke

Phase 2

Safety Evaluation of 3K3A-APC in Ischemic Stroke

CompletedNCT02222714

ZZ Biotech, LLCIschemic Stroke

Start: 2014-10-31End: 2017-06-29Updated: 2018-11-08

Phase 3

Efficacy and Safety Evaluation of 3K3A-APC in Ischemic Stroke

WithdrawnNCT05484154

ZZ Biotech, LLCIschemic Stroke

Start: 2024-10-31End: 2026-10-31Updated: 2024-10-01

Related Papers

Abstract WP139: MRI Evaluation and Functional Assessment of Brain Injury Improvement After 3K3A-Activated Protein C Treatment for Murine White Matter Stroke

Stroke2019-01-30

Final Results of the RHAPSODY Trial: A Multi‐Center, Phase 2 Trial Using a Continual Reassessment Method to Determine the Safety and Tolerability of 3K3A‐APC, A Recombinant Variant of Human Activated Protein C, in Combination with Tissue Plasminogen Activator, Mechanical Thrombectomy or both in Moderate to Severe Acute Ischemic Stroke

Annals of Neurology2018-11-19142 citations

Abstract WP90: Activate Protein C Analog Protects Ischemic Injury of Subcortical White Matter in Mice

Stroke2018-01-221 citations

Selecting Patients for Intra-Arterial Therapy in the Context of a Clinical Trial for Neuroprotection

Stroke2016-11-0220 citations